CTNMContineum Therapeutics, Inc.

Healthcare
$13.21+16% 1Y

The financials

Contineum Therapeutics, Inc. by the numbers

The next results filing is expected around Oct 29, 2026, the same week as a year ago.

Contineum Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$17M−$18Mn/a
Net income−$15M−$16Mn/a
Diluted EPS−$0.40−$0.62n/a

Biotechnology

The closest names by size in the same industry

Compare peers
EPRX-2.7%
EUPRAXIA PHARMACEUTICALS INC.
ARVN+0.80%
ARVINAS, INC.
PROK+5.0%
PROKIDNEY CORP.
ALLO-1.8%
Allogene Therapeutics, Inc.
ALT-2.4%
Altimmune, Inc.
PBYI+1.6%
PUMA BIOTECHNOLOGY, INC.